J. Krauss

J. Krauss, T. Carey, C. Bradford, 1996, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes

J. Krauss, A. Chang, M. Cameron, 1996, Cancer Immunology, Immunotherapy.

Tumor reactivity of immune T cells in short-term culture

J. Krauss, S. Shu, Jeannine M. Stein, 1996, Cancer Immunology, Immunotherapy.

Immunobiologic effects of cytokine gene transfer of the B16-BL6 melanoma.

J. Krauss, A. Chang, M. Cameron, 1993, Archives of otolaryngology--head & neck surgery.

Strategies of lymphocyte activation for the adoptive immunotherapy of metastatic cancer: a review.

J. Krauss, A. Chang, S. Strome, 1993, Journal of hematotherapy.

AN EFFICIENT ONE-STEP SYNTHESIS OF 3-OXOALKANENITRILES

J. Krauss, L. Townsend, T. L. Cupps, 1983 .

Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma.

J. Krauss, J. Cui, D. Eitzman, 1996, Blood.

2-Mercaptoethanol treatment improves measurement of an IgMkappa M-protein by capillary electrophoresis.

J. Krauss, D. Keren, J. L. Carey, 2001, Clinical chemistry.

Treatment of subcutaneous tumor with adoptively transferred T cells.

J. Krauss, S. Shu, Liaomin Peng, 1997, Cellular immunology.

Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT).

R. Advani, R. Gascoyne, T. Habermann, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Monocyte chemoattractant protein inhibits the generation of tumor-reactive T cells.

J. Krauss, S. Shu, Liaomin Peng, 1997, Cancer research.

Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules

J. Krauss, J. Finke, J. Liu, 1998, Cancer Immunology, Immunotherapy.

Systemic T cell adoptive immunotherapy of malignant gliomas.

J. Krauss, G. Barnett, R. Prayson, 1998, Journal of neurosurgery.

Activated lymph node T cells for systemic adoptive immunotherapy of malignant glioma

J. Krauss, G. Barnett, David W. Miller, 1997 .

Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma

R. Gascoyne, J. Krauss, S. Horning, 2011 .

Successful Treatment of Refractory Low Grade Duodenal Lymphoma With Rituximab, an Anti-cd20 Monoclonal Antibody

J. Krauss, Shazia Ahmed, N. Gunaratnam, 2003, American journal of clinical oncology.

Cytokines as an adjuvant to tumor vaccines: Efficacy of local methods of delivery

J. Krauss, A. Chang, A. Aruga, 1997, Annals of Surgical Oncology.

OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC

J. Desai, R. Govindan, J. Krauss, 2019, Journal of Thoracic Oncology.

Tumor immunology.

J. Krauss, A. Chang, G. Plautz, 1997, JAMA.

Targeted Gene Transfer for Adenocarcinoma Using a Combination of Tumor‐specific Antibody and Tissue‐specific Promoter

S. Kudoh, J. Krauss, A. Chang, 1998, Japanese journal of cancer research : Gann.

An in vivo animal model of gene therapy for leukocyte adhesion deficiency.

J. Krauss, K. Weber, J. Wilson, 1991, The Journal of clinical investigation.

Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

R. Schilsky, J. Krauss, C. Calfa, 2022, JCO precision oncology.

Monocyte Chemoattractant Protein Inhibits the Generation of Tumor-reactive T Cells 1

J. Krauss, S. Shu, Liaomin Peng, 2022 .

Low IgE monoclonal gammopathy level in serum highlights 20‐yr survival in a case of IgE multiple myeloma

J. Krauss, D. Keren, J. L. Carey, 2007, European journal of haematology.

Pilot Study of Personalized Video Visit Summaries for Patients With Cancer

J. Krauss, M. Kirch, L. An, 2018, JCO clinical cancer informatics.

Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001.

J. Krauss, G. Demetri, R. Doebele, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

SYNTHESIS OF VERSATILE C–NUCLEOSIDE PRECURSORS AND CERTAIN C–NUCLEOSIDES1

J. Krauss, L. Townsend, T. L. Cupps, 1983 .

Vulvar pseudotumoral acyclovir-resistant herpes in an HIV-negative, non-immunosuppressed patient: A therapeutic challenge

J. Krauss, L. Washer, H. Haefner, 2021, International Journal of Women's Dermatology.

Efficacy of the Motivational Interviewing–Walk Intervention for Chemotherapy-Induced Peripheral Neuropathy and Quality of Life During Oxaliplatin Treatment

J. Krauss, K. Resnicow, R. Ploutz-Snyder, 2021, Cancer nursing.

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.

A. Drilon, J. Krauss, G. Demetri, 2019, The Lancet. Oncology.

Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy

Ryan E. Mills, David C. Smith, A. Chinnaiyan, 2017, Oncotarget.

Development, implementation, and initial evaluation of a foundational open interoperability standard for oncology treatment planning and summarization

Jeremy L. Warner, Kevin S. Hughes, John C. Krauss, 2015, J. Am. Medical Informatics Assoc..

Emerging Systemic Therapies for Colorectal Cancer

J. Krauss, Christine M. Veenstra, 2018, Clinics in Colon and Rectal Surgery.

Secretion of biologically active superantigens by mammalian cells.

J. Krauss, S. Shu, John C. Krauss, 1997, Journal of hematotherapy.

Secretion of Both IL‐2 and IL‐4 by Tumor Cells Results in Rejection and Immunity

J. Krauss, A. Chang, S. Strome, 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Retroviral-mediated gene transfer in human bone marrow cells growth in continuous perfusion culture vessels.

B. Palsson, J. Krauss, M. Clarke, 1995, Blood.

Expression of retroviral transduced human CD18 in murine cells: an in vitro model of gene therapy for leukocyte adhesion deficiency.

J. Krauss, J. Wilson, R. Todd, 1991, Human gene therapy.

RETROVIRAL TRANSDUCED HUMAN CD 18 IN MURINE CELLS 223

J. Krauss, J. Wilson, R. Todd, 2022 .

Hematopoietic stem cell gene replacement therapy.

J. Krauss, John C. Krauss, 1992, Biochimica et biophysica acta.

Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001.

J. Krauss, R. Doebele, J. Wolf, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes.

J. Krauss, G. Plautz, H. Kagamu, 1996, Cancer research.

Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor.

J. Krauss, A. Chang, M. Cameron, 1996, Cancer gene therapy.

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

J. Desai, R. Govindan, J. Krauss, 2020, The New England journal of medicine.

SO-24 AMG 510, a novel small molecule inhibitor of KRAS G12C, for patients with advanced gastrointestinal cancers: Results from the CodeBreak 100 phase 1 trial

J. Desai, J. Krauss, Tae Won Kim, 2020 .

T Cell-Mediated Tumor Rejection Displays Diverse Dependence Upon Perforin and IFN-γ Mechanisms That Cannot Be Predicted From In Vitro T Cell Characteristics1

J. Krauss, G. Plautz, P. Cohen, 2000, The Journal of Immunology.

Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001.

J. Krauss, R. Doebele, L. Paz-Ares, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer.

J. Desai, J. Krauss, Keunchil Park, 2020 .

Advances in Brief Isolation Based on L-Selectin Expression of Immune Effector T Cells Derived from Tumor-draining Lymph Nodes 1

Joseph, Kââ, E. Plautz, 2006 .

Inferring a consensus problem list using penalized multistage models for ordered data.

John C. Krauss, Philip S. Boonstra, J. Krauss, 2020, The annals of applied statistics.

Concurrent induction of CD4+ and CD8+ T cells during tumor growth with antitumor reactivity in adoptive immunotherapy.

J. Krauss, A. Chang, M. Cameron, 1997, Journal of immunotherapy.

A randomized, controlled trial of Panax quinquefolius extract (CVT-E002) to reduce respiratory infection in patients with chronic lymphocytic leukemia.

E. Shaw, A. Falsey, J. Krauss, 2012, The journal of supportive oncology.

Do treatment patterns alter beliefs cancer patients hold regarding oral oncolytic agents?

B. Given, J. Krauss, A. Sikorskii, 2018, Psycho-oncology.

Rituximab extended schedule or retreatment trial for low tumour burden non‐follicular indolent B‐cell non‐Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402

R. Gascoyne, T. Habermann, J. Krauss, 2016, British journal of haematology.

Self-Guided Online Cognitive Behavioral Strategies for Chemotherapy-Induced Peripheral Neuropathy: A Multicenter, Pilot, Randomized, Wait-List Controlled Trial.

David A. Williams, J. Krauss, E. Smith, 2017, The journal of pain : official journal of the American Pain Society.

Patient Engagement With an Automated Telephone Symptom Management Intervention: Predictors and Outcomes.

B. Given, J. Krauss, A. Sikorskii, 2020, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

315O Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort

J. Krauss, R. Yaeger, M. Fakih, 2022, Annals of Oncology.

NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer.

J. Krauss, N. Wolmark, M. Deutsch, 2018, Journal of Clinical Oncology.

Challenges to the design and testing supportive interventions for cancer patients treated with oral oncolytic agents

B. Given, J. Krauss, A. Sikorskii, 2018, Supportive Care in Cancer.

543P Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

A. Drilon, J. Krauss, R. Doebele, 2020 .

Effects of depressive symptomatology on cancer‐related symptoms during oral oncolytic treatment

B. Given, J. Krauss, A. Sikorskii, 2018, Psycho-oncology.

CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).

J. Krauss, T. Burns, D. Hong, 2020, Journal of Clinical Oncology.

Evaluation of biliary toxicity in patients with hepatic artery infusion pumps.

J. Krauss, Allison J Schepers, R. McDevitt, 2023, Journal of Oncology Pharmacy Practice.

Self-guided online cognitive behavioral strategies for chemotherapy-induced peripheral neuropathy (CIPN): A multicenter, single blind, randomized, wait-list controlled trial.

David A. Williams, J. Krauss, E. Smith, 2017 .

An Automated Intervention Did Not Improve Adherence to Oral Oncolytic Agents While Managing Symptoms: Results From a Two-Arm Randomized Controlled Trial.

B. Given, J. Krauss, V. Champion, 2018, Journal of pain and symptom management.

Potential mediators of improvement in painful chemotherapy-induced peripheral neuropathy via a web-based cognitive behavioural intervention.

J. Krauss, E. Smith, D. Barton, 2018, Canadian oncology nursing journal = Revue canadienne de nursing oncologique.

Tubulogenesis from isolated single cells of adult mammalian kidney: clonal analysis with a recombinant retrovirus.

J. Krauss, H. Humes, D. A. Cieslinski, 1996, The American journal of physiology.

Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.

C. James, J. Uhm, B. Scheithauer, 2011, International journal of radiation oncology, biology, physics.

Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines Who are Suspected DPYD Variant Carriers Based on a Genetic Data Repository

J. Krauss, P. Swiecicki, D. Hertz, 2023, Clinical pharmacology and therapeutics.

Data Sharing to Support the Cancer Journey in the Digital Era.

Richard Moldwin, Jeremy L Warner, Suzanne E. Maddux, 2016, Journal of oncology practice.

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

J. Krauss, M. Ducreux, J. Tabernero, 2023, The Lancet.

Abstract 2257: Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (Durva) plus tremelimumab (T) following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) progressing on chemotherapy: NSABP FC-

D. Heron, J. Krauss, K. Pogue-Geile, 2019, Clinical Research (Excluding Clinical Trials).

Enhancement of Immune Reactivity in the Lymph Nodes Draining a Murine Melanoma Engineered to Elaborate Interleukin‐4

J. Krauss, A. Chang, S. Strome, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Development, implementation, and initial evaluation of a foundational open interoperability standard for oncology treatment planning and summarization

Suzanne E. Maddux, George A. Koromia, L. Esserman, 2015, J. Am. Medical Informatics Assoc..

OA03.03 Sotorasib in Combination with RMC-4630, a SHP2 Inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumors

J. Krauss, C. Langer, K. Marrone, 2022, Journal of Thoracic Oncology.

Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2.

J. Krauss, C. Allegra, G. Yothers, 2022, Journal of Clinical Oncology.

Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study.

J. Krauss, G. Plautz, M. Strome, 2000, Archives of otolaryngology--head & neck surgery.

NSABP FC-9: Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (D) plus tremelimumab (T) following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) progressing on chemotherapy.

D. Heron, J. Krauss, M. Fakih, 2018 .